A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

This study is looking at a treatment called BV-AVD for people with newly diagnosed, early-stage Hodgkin lymphoma that has large tumors (bulky disease). BV-AVD combines Brentuximab vedotin, Doxorubicin, Vinblastine, and Dacarbazine, along with Pembrolizumab. Brentuximab vedotin is an antibody-drug conjugate (ADC), which means it's a targeted treatment designed to kill cancer cells while sparing healthy ones. The study aims to see how long people live without their cancer growing or spreading (progression-free survival) over three years. To join, you must be 18 or older, have a specific type of Hodgkin lymphoma confirmed by a biopsy, and have not received any prior treatment for your disease. The current status of this study is unclear, and it plans to enroll 71 participants.

Study design: This is an interventional study, meaning participants will receive specific treatments. It plans to enroll 71 participants.
What's involved: Not specified in the trial record.
Compensation: Not stated in the trial record.
Follow-up: Participants will be followed for three years to measure progression-free survival.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Recruiting

PHASE2Ages 18+InterventionalTreatment

Memorial Sloan Kettering Cancer Center

~71 participants

Updated 2026-04-23 on ClinicalTrials.gov

What's tested:Brentuximab vedotinDoxorubicinVinblastineDacarbazinePembrolizumabGemcitabine

At a glance

Recruiting sites

7 of 8 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

progression-free survival

Measured over 3 years

Conditions

Hodgkin Lymphoma

NCT06377566

Where you'd take part

This study runs at 8 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge, New Jerseystudy coordinator listed
Recruiting
Memorial Sloan Kettering Bergen (All Protocol Activities)
Montvale, New Jerseystudy coordinator listed
Recruiting
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New Yorkstudy coordinator listed
Recruiting
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Middletown, New Jerseystudy coordinator listed
Recruiting
Memorial Sloan Kettering Nassau (All Protocol Activities)
Uniondale, New Yorkstudy coordinator listed
Recruiting
Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)
Commack, New Yorkstudy coordinator listed
Recruiting
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, New Yorkstudy coordinator listed
Recruiting
University of Miami
Miami, Floridastudy coordinator listed
Not yet recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

Robert Stuver, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Robert Stuver, MD

[email protected]

646-608-4308

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Histological diagnosis of classical, CD30-positive Hodgkin lymphoma confirmed at enrolling institution.

Ann Arbor stage I or II FDG-avid disease by FDG-PET/CT.

Disease bulk defined as any lymph node mass with transverse maximal diameter ≥ 7.0 cm or coronal maximal diameter ≥ 7.0 cm on CT imaging.

Age 18 and over.

ECOG Performance Status ≤ 2

Females of childbearing age must be on an acceptable form of birth control per institutional standards during the treatment period.

Males must consistently use an acceptable form of contraception per institutional standards during the treatment period.

Exclusion

Prior systemic therapy or radiation therapy for Hodgkin lymphoma (excluding corticosteroids)

Cardiac ejection fraction \< 50% as measured by echocardiogram.

Platelet count ≤ 75,000/µL.

Hemoglobin level ≤ 7.0 mg/dL.

Absolute neutrophil count ≤ 1.0 K/µL.

Serum creatinine clearance \< 30 mL/minute as estimated by the Cockcroft-Gault Method.

Transaminase levels \> 3 times the upper limit of normal in the absence of a history of Gilbert's disease or hepatic involvement. In patients with Gilbert's disease, \> 5 times the upper limit of normal is exclusionary.

Total bilirubin ≥ 1.5 the upper limit of normal in the absence of a history of Gilbert's disease or hepatic involvement. In patients with Gilbert's disease, \> 3 times the upper limit of normal is exclusionary.

Pre-existing peripheral neuropathy ≥ grade 2 prior to participation.

Known pregnancy or breast-feeding

Active viral infection with hepatitis B or hepatitis C. For hepatitis B, patients who are seropositive (hepatitis B core Ab positive) are permitted if HBV DNA is negative by PCR. For hepatitis C, patients who are seropositive (hepatits C Ab positive) are eligible if HCV DNA is negative by PCR and curative therapy has been completed.

Concurrent malignancy requiring active therapy within the last 2 years with the exception of basal cell or squamous cell carcinoma limited to the skin, carcinoma in situ of the cervix, breast or localized prostate cancer. Adjuvant hormonal therapy for cancer previously treated for curative intent is permitted.

Patients with autoimmune conditions requiring active, ongoing systemic immunosuppressive therapy.

Medical illness unrelated to Hodgkin lymphoma which in the opinion of the treating physician and/or principal investigator makes participation inappropriate.

What this trial measures

progression-free survival3 years

Trialytics